Published Date: 23 Apr 2023
Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.
Read Full NewsFDA approves a label update for the BEAR implant, which was previously approved in 2020.
Physicians experience significant challenges with increasing administrative burdens impacting patient care. Study shows AI scribes can help reduce burnout.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 23, 2026.
Jerel Banks, MD, PhD, chief executive officer of Benitec Biopharma, reviews early phase 1b/2a clinical signals, mechanism, and next steps for BB-301 in oculopharyngeal muscular dystrophy.
Benitec Biopharma reveals promising results for BB-301, a gene therapy showing significant improvements in swallowing function for OPMD patients.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ALS Treatment pathways!
GLP-1 Discontinuation Results in Significant Weight Regain, With Michael Weintraub, MD
1.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
2.
Novel Agent for Chronic GVHD Wins FDA Approval
3.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
4.
Kate Middleton and Remission: Oncologists Weigh In
5.
Did U.S. Government Play a Role in Remote Tribe's Widespread Illness and Cancer?
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Understanding Fibrosarcoma: What You Need to Know
3.
What Is Gastrinoma? Understanding This Rare Tumor and Its Treatment Options
4.
Tumor Evolution: Signaling, Plasticity, and Intratumor Heterogeneity in Cancer
5.
Liquid Biopsy: Revolutionizing Precision Oncology in Hematological Malignancies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
4.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation